Supercharged immune cells take on deadly brain tumors
NCT ID NCT07579208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an IV, to see which method is safer. The study involves 36 adults and focuses on side effects and the best way to deliver the cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered natural killer (NK) cells
- What this could lead to
- If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few options.
- What could go wrong
- This is a very early Phase 1 trial with only 36 people. It is designed mainly to check safety, not yet to prove the treatment works. There may be side effects from the cells or the delivery method.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIMERA ANTIGEN RECEPTOR (CAR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Could a parasite drug fight childhood brain tumors?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?